Menu
Menu
Targeting the pathobiology of neutrophil extracellular traps
Citryll – a dutch biotech company – is taking a new approach to treat autoimmune and other human inflammatory diseases like lupus, vasculitis, pulmonary fibrosis, asthma, rheumatoid arthritis and organ damage due to sepsis, by targeting and inhibiting the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules instead of broadly targeting inflammation or acquired immunity.
Scientific Approach
Citryll targets Neutrophil Extracellular Traps (NET) formation with a human antibody CIT-013 that interferes with the formation of NETs as well as promotes the clearance of NETs. A range of human diseases with potential for SLE, RA, vasculitis, asthma, IPF and other indications can be treated with CIT-013.
CIT-013 Development
A first human study started in the summer of 2021 starting with a Single Ascending Dose (SAD) study in healthy volunteers. GMP production and formulation of the antibody drug product was carried out by Citryll’s CMC partner Lonza and CTA enabling studies were finalised in Spring 2021.
Latest News
Citryll announces appointments of Eduardo Bravo as CEO and Tim Schenk as CBO
Mr. Bravo has held multiple CEO positions, including in the autoimmune space, and served as Chair on various Boards.
Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors
Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.
Latest News
Citryll announces appointments of Eduardo Bravo as CEO and Tim Schenk as CBO
Mr. Bravo has held multiple CEO positions, including in the autoimmune space, and served as Chair on various Boards.
Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors
Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.
Citryll Appoints Sjoerd van Gorp as Director of Operations
Sjoerd will work closely with key development partners to expand the therapeutic utilities of CIT-013, its clinical development candidate and derivatives.